These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5841260)

  • 21. Pharmacological actions of caerulein.
    Erspamer V; Bertaccini G; De Caro G; Endean R; Impicciatore M
    Experientia; 1967 Sep; 23(9):702-3. PubMed ID: 6062877
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparison of hypotensive activities between synthetic bradykinin and bradykinin analogs in rats].
    Kameyama T; Sasaki K
    Nihon Yakurigaku Zasshi; 1970 Sep; 66(5):503-10. PubMed ID: 5529892
    [No Abstract]   [Full Text] [Related]  

  • 23. Kinetic studies on the formation and destruction of the vasopressor polypeptide, substance A.
    Pavesi L; Huggins CG
    Biochem Pharmacol; 1968 Aug; 17(8):1699-707. PubMed ID: 4299738
    [No Abstract]   [Full Text] [Related]  

  • 24. [Synthesis and pharmacological properties of new 4-chlorophenoxyacetic acid derivatives].
    Szadowska A; Mazur M; Graczyk J; Kiełek MB; Guryn R; Mikołajewska H; Glinka R; Kotełko B
    Acta Pol Pharm; 1982; 39(5-6):361-72. PubMed ID: 6892086
    [No Abstract]   [Full Text] [Related]  

  • 25. [Synthesis and pharmacological study of various 2-(alkylaminoalkyl)mercapto-5-aryl-1,3,4-oxadiazoles].
    Mazzone G; Bonina F; Arrigo-Reina R
    Farmaco Sci; 1977 Jun; 32(6):414-29. PubMed ID: 872921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of polypeptide activity by cysteine analogs: structure-activity relationship.
    Potter DE; Walaszek EJ
    Pharmacology; 1971; 5(6):359-71. PubMed ID: 5119544
    [No Abstract]   [Full Text] [Related]  

  • 27. Possible physiological role of new peptide fragments released from bovine high molecular weight kininogen by plasma kallikrein.
    Oh-ishi S; Katori M; Nam Han Y; Iwanaga S; Kato H
    Biochem Pharmacol; 1977 Jan; 26(2):115-20. PubMed ID: 138423
    [No Abstract]   [Full Text] [Related]  

  • 28. [On the biological properties of some fibrinogen degradation products (FDP)].
    Malofiejew M
    Rocz Akad Med Im Juliana Marchlewskiego Bialymst Suppl; 1968; 23():1-65. PubMed ID: 4310706
    [No Abstract]   [Full Text] [Related]  

  • 29. Occurrence of physalaemin in extracts of the skin of Physalaemus fuscumaculatus and its pharmacological actions on extravascular smooth muscle.
    Bertaccini G; Cei JM; Erspamer V
    Br J Pharmacol Chemother; 1965 Oct; 25(2):363-79. PubMed ID: 5866718
    [No Abstract]   [Full Text] [Related]  

  • 30. [A biological active peptide in the skin of lampreys (Eudontomyzon danfordi vladykovi)].
    Fischer G; Albert W
    Z Naturforsch B; 1971 Oct; 26(10):1021-3. PubMed ID: 4401625
    [No Abstract]   [Full Text] [Related]  

  • 31. Differentiation of bradykinin receptors and of kininases with conformational analogues of bradykinin.
    LeDuc LE; Marshall GR; Needleman P
    Mol Pharmacol; 1978 May; 14(3):413-21. PubMed ID: 207969
    [No Abstract]   [Full Text] [Related]  

  • 32. A pharmacological analysis of aspirin.
    Collier HO
    Adv Pharmacol (1962); 1969; 7():333-405. PubMed ID: 4984754
    [No Abstract]   [Full Text] [Related]  

  • 33. Development of bradykinin antagonists: structure-activity relationships for new categories of antagonist sequences.
    Vavrek RJ; Stewart JM
    Adv Exp Med Biol; 1989; 247B():395-400. PubMed ID: 2610083
    [No Abstract]   [Full Text] [Related]  

  • 34. Synthesis and pharmacological screening of new angiotensin converting enzyme inhibitors.
    Gubert S; Braso MA; Sacristán A; Ortiz JA
    Farmaco; 1990 Jan; 45(1):59-79. PubMed ID: 2186741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New synthetic antagonists of bradykinin.
    Schachter M; Uchida Y; Longridge DJ; Labedz T; Whalley ET; Vavrek RJ; Stewart JM
    Br J Pharmacol; 1987 Dec; 92(4):851-5. PubMed ID: 3427282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological data on phyllokinin (bradykinyl-isoleucyl-tyrosine o-sulphate) and bradykinyl-isoleucyl-tyrosine.
    Anastasi A; Bertaccini G; Erspamer V
    Br J Pharmacol Chemother; 1966 Sep; 27(3):479-85. PubMed ID: 5970899
    [No Abstract]   [Full Text] [Related]  

  • 37. Studies on leukokinins. 3. Pharmacological activities of leukokinins M and PMN.
    Freer R; Chang J; Greenbaum LM
    Biochem Pharmacol; 1972 Dec; 21(23):3107-10. PubMed ID: 4675450
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro and in vivo characterization of bradykinin B2 receptors in the rabbit and the guinea pig.
    Gobeil F; Filteau C; Pheng LH; Jukic D; Nguyen-Le XK; Regoli D
    Can J Physiol Pharmacol; 1996 Feb; 74(2):137-44. PubMed ID: 8723025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in beta-adrenoceptor-blocking activity produced by chemical modifications in the practolol molecule.
    Weinstock M; Schechter Y; Erez M; Shtacher G
    Eur J Pharmacol; 1974 May; 26(2):191-7. PubMed ID: 4152806
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of ranatensin, a polypeptide from frog skin, on isolated smooth muscle.
    Clineschmidt BV; Geller RG; Govier WC; Pisano JJ; Tanimura T
    Br J Pharmacol; 1971 Apr; 41(4):622-8. PubMed ID: 4325450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.